These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21477724)

  • 1. Editorial comment.
    Boorjian SA; Blute ML
    Urology; 2011 Apr; 77(4):950-1. PubMed ID: 21477724
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment.
    Macaluso JN
    Urology; 2014 Feb; 83(2):384. PubMed ID: 24315303
    [No Abstract]   [Full Text] [Related]  

  • 3. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?].
    Matveev BP; Bukharkin BV
    Urologiia; 2003; (6):6-10. PubMed ID: 14708235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial comment.
    Pinkawa M
    J Urol; 2010 Feb; 183(2):639; discussion 639-40. PubMed ID: 20018310
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment.
    Williams SG
    J Urol; 2010 Feb; 183(2):639; discussion 639-40. PubMed ID: 20018309
    [No Abstract]   [Full Text] [Related]  

  • 6. [Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate].
    Boccon-Gibod L
    Prog Urol; 1997 Feb; 7(1):97-8. PubMed ID: 9116748
    [No Abstract]   [Full Text] [Related]  

  • 7. Controversies in the treatment of prostate cancer with maximal androgen deprivation.
    McLeod DG; Moul JW
    Surg Oncol Clin N Am; 1995 Apr; 4(2):345-59. PubMed ID: 7796290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neoadjuvant hormone therapy with total radical prostatectomy: intermediate results].
    Hermans BP; Lorge F; Wese FX; Opsomer RJ; Van Cangh PJ
    Acta Urol Belg; 1996 Mar; 64(1):27-31. PubMed ID: 8659332
    [No Abstract]   [Full Text] [Related]  

  • 9. [Future prospects for primary hormone therapy in localized and locally advanced prostate cancer].
    Akaza H; Hirao Y; Labrie F; Soloway MS
    Hinyokika Kiyo; 2003 Dec; 49(12):771-7. PubMed ID: 14978964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy and early adjuvant hormonal therapy for pTxN+ adenocarcinoma of the prostate.
    Seay TM; Blute MC; Zincke H
    Urology; 1997 Dec; 50(6):833-7. PubMed ID: 9426709
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical impact of neoadjuvant treatment to radical prostatectomy in locally advanced prostatic cancer].
    Villavicencio H; Laguna P; Ponce de Léon J
    Actas Urol Esp; 1994 May; 18 Suppl():404-8. PubMed ID: 8073926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
    Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
    Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of neoadjuvant hormonal therapy on the outcome of laparoscopic radical prostatectomy: a matched pair analysis.
    Maldonado-Valadez R; Teber D; Erdogru T; Safi KC; Frede T; Rassweiler J
    J Urol; 2006 Jun; 175(6):2092-6. PubMed ID: 16697810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer: non-metastatic.
    Wilt T
    Clin Evid; 2002 Jun; (7):812-23. PubMed ID: 12230707
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
    Rogers C
    J Urol; 2003 Nov; 170(5):1955; author reply 1955-6. PubMed ID: 14575038
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment on: Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy.
    Parker C
    Eur Urol; 2007 Dec; 52(6):1651-2. PubMed ID: 18074437
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
    Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
    BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
    Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
    Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant androgen-deprivation therapy prior to radical prostatectomy: con.
    Paulson DF
    Urology; 1996 Oct; 48(4):539-40. PubMed ID: 8886056
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
    Messing EM
    J Urol; 2003 Nov; 170(5):1955; author reply 1955-6. PubMed ID: 14532828
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.